Evogene Research and Development Expenses 2012-2024 | EVGN

Evogene research and development expenses from 2012 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

Evogene Research and Development Expenses 2012-2024 | EVGN

Evogene research and development expenses from 2012 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$171.5B
Vertex Pharmaceuticals (VRTX)$121.6B
Gilead Sciences (GILD)$111.4B
Bristol Myers Squibb (BMY)$110.2B
Regeneron Pharmaceuticals (REGN)$93B
CSL (CSLLY)$90B
GSK (GSK)$76.4B
Argenex SE (ARGX)$35.6B
Alnylam Pharmaceuticals (ALNY)$35.3B
BioNTech SE (BNTX)$26.5B
Biogen (BIIB)$25.3B
Illumina (ILMN)$23.9B
Moderna (MRNA)$21B
BeiGene (BGNE)$19.9B
Genmab (GMAB)$14.9B
Incyte (INCY)$14.7B
Exact Sciences (EXAS)$12.9B
BioMarin Pharmaceutical (BMRN)$12.7B
Vaxcyte (PCVX)$12B
Bio-Techne Corp (TECH)$11.9B
Sarepta Therapeutics (SRPT)$11.8B
Insmed (INSM)$11.7B
QIAGEN (QGEN)$9.8B
Exelixis (EXEL)$9.7B
Bio-Rad Laboratories (BIO.B)$9.3B
Revolution Medicines (RVMD)$9.2B
Intra-Cellular Therapies (ITCI)$9.2B
Roivant Sciences (ROIV)$8.6B
Viking Therapeutics (VKTX)$8.1B
Legend Biotech (LEGN)$8.1B